# Lisa M. McShane

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lisa-m-mcshane/

## Facts

| Field | Value |
| --- | --- |
| Citations | 58,194 |
| Field | Cancer Genomics and Diagnostics |
| h-index | 90 |
| i10-index | 181 |
| Last Known Institution | National Institutes of Health |
| OpenAlex ID | https://openalex.org/A5040419960 |
| ORCID iD | https://orcid.org/0000-0001-8195-3206 |
| Works | 387 |

## Researcher papers

- [Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)](https://scholariq.org/papers/reporting-recommendations-for-tumor-marker-prognostic-studies-remark-3/)
- [Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group](https://scholariq.org/papers/assessment-of-ki67-in-breast-cancer-recommendations-from-the-international-ki67/)
- [Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update](https://scholariq.org/papers/estrogen-and-progesterone-receptor-testing-in-breast-cancer-asco-cap-guideline/)
- [REporting recommendations for tumour MARKer prognostic studies (REMARK)](https://scholariq.org/papers/reporting-recommendations-for-tumour-marker-prognostic-studies-remark/)
- [REporting recommendations for tumor MARKer prognostic studies (REMARK)](https://scholariq.org/papers/reporting-recommendations-for-tumor-marker-prognostic-studies-remark-2/)
- [Reporting Recommendations for Tumor Marker Prognostic Studies](https://scholariq.org/papers/reporting-recommendations-for-tumor-marker-prognostic-studies/)
- [Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group](https://scholariq.org/papers/assessment-of-ki67-in-breast-cancer-updated-recommendations-from-the/)
- [REporting recommendations for tumor MARKer prognostic studies (REMARK)](https://scholariq.org/papers/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/)
- [Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project](https://scholariq.org/papers/establishing-guidelines-to-harmonize-tumor-mutational-burden-tmb-in-silico/)
- [REporting recommendations for tumour MARKer prognostic studies (REMARK)](https://scholariq.org/papers/reporting-recommendations-for-tumour-marker-prognostic-studies-remark-2/)
- [Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project](https://scholariq.org/papers/aligning-tumor-mutational-burden-tmb-quantification-across-diagnostic-platforms/)

## Researcher topics

- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Statistical Methods in Clinical Trials](https://scholariq.org/topics/statistical-methods-in-clinical-trials/)
- [Radiomics and Machine Learning in Medical Imaging](https://scholariq.org/topics/radiomics-and-machine-learning-in-medical-imaging/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [National Institutes of Health](https://scholariq.org/institutions/national-institutes-of-health/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.